DV Biomed CoROCO:6539 -0.24%68 EBITDA Margin % is 10.60% as of Dec. 2025, which is 59% below its 10-year median of 26.08. GuruFocus rates ROCO:6539 with a GF Score™ of 68/100 and a GF Value™ of NT$70.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 953 Drug Manufacturers companies, DV Biomed Co ranks worse than 65.58% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. DV Biomed Co's EBITDA for the
six
months ended in Dec. 2025 was NT$43.1 Mil. DV Biomed Co's Revenue for the
six
months ended in Dec. 2025 was NT$406.4 Mil. Therefore, DV Biomed Co's EBITDA margin for the quarter that ended in Dec. 2025 was 10.60%.
DV Biomed Co (ROCO:6539) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
DV Biomed Co EBITDA Margin % Related Terms
DV Biomed Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for DV Biomed Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6539 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DV Biomed Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DV Biomed Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DV Biomed Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where DV Biomed Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DV Biomed Co (ROCO:6539) has a EBITDA Margin % of 10.60% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DV Biomed Co and its competitors. This is 59% below median its historical median of 26.08. Over the past decade, DV Biomed Co's EBITDA Margin % has ranged from 5.92 to 31.90. According to the industry distribution chart, DV Biomed Co ranks #625 out of 953 companies in the Drug Manufacturers industry, placing it in the top 65.6%.
Is DV Biomed Co's EBITDA Margin % too high?
DV Biomed Co's current EBITDA Margin % of 10.60% is 59% below median its 10-year median of 26.08. Over the past 10 years, this metric has ranged from a low of 5.92 to a high of 31.90. The Drug Manufacturers industry median EBITDA Margin % is 12.49. DV Biomed Co's value of 10.60% is 15.1% below this industry median. Based on the distribution chart, DV Biomed Co ranks #625 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, DV Biomed Co has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DV Biomed Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DV Biomed Co ranks #625 out of 953 companies for EBITDA Margin %. This places DV Biomed Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. DV Biomed Co's value of 10.60% is 15.1% below this benchmark. Historically, DV Biomed Co's own EBITDA Margin % has ranged from 5.92 to 31.90 over the past decade. While the company's 10-year median is 26.08 vs. the industry median of 12.49, DV Biomed Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DV Biomed Co's current EBITDA Margin % of 10.60% is 15.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DV Biomed Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DV Biomed Co's current EBITDA Margin % is 10.60%, which is 59% below median its own 10-year median of 26.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DV Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, DV Biomed Co (ROCO:6539) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.47, compared to a current price of NT$41.65 — trading 40.9% below its estimated fair value. The current EBITDA Margin % is 10.60%, which is 59% below median its 10-year median of 26.08 and 15.1% below the Drug Manufacturers industry median of 12.49. DV Biomed Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DV Biomed Co (ROCO:6539), the current EBITDA Margin % is 10.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DV Biomed Co (ROCO:6539) Overvalued in 2026?
Based on GuruFocus' analysis, DV Biomed Co stock appears to be undervalued.
The current stock price of NT$41.65 is trading 40.9% below its estimated GF Value™ of NT$70.47.
GuruFocus considers DV Biomed Co to be Possible Value Trap.
Key valuation signals for ROCO:6539:
EBITDA Margin %: 10.60% (59% below median its 10-year median of 26.08)
GF Value™: NT$70.47 vs. price of NT$41.65 (40.9% below fair value)
Industry Position: 15.1% below the Drug Manufacturers median (#625 of 953)
No single metric tells the full story. See the ROCO:6539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DV Biomed Co Ltd provides medical supplies, skincare, and healthcare products. Its products include Perfectin and L'AMOUR Isis. The company also provides medical materials and needles (medicine), and healthcare products.
68GF Score
Get the complete analysis for ROCO:6539
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6539 has been successfully added to your 
